9 terminated. 9 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Terminated 9 |
| Phase 2 | 4 | Terminated 4 |
Follow Electrocardiogram: new trials by email Literature Review of Electrocardiogram trials Research Report on Electrocardiogram
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes KPT-8602, Inqovi, Bone marrow aspirate - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 3 | 2023-11-14 | 2025-12-02 |
| BMS-986253 in Myelodysplastic Syndromes Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Decitabine, Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Cedazuridine, BMS-986253 - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2022-11-29 | 2025-09-30 |
| Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas Rituximab, Etoposide, Copanlisib - Burkitt Lymphoma, High-grade B-cell Lymphoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 8 | 2022-03-24 | 2024-07-09 |
| T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers IL-2 (Aldesleukin), Cyclophosphamide, KK-LC-1 TCR - Kita-kyushu Lung Cancer Antigen 1, Human | Phase 1 | Terminated | National Cancer Institute (NCI) | 36 | 2022-03-08 | 2025-12-02 |
| Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma LMB-100, ipilimumab, Diphenhydramine - Mesothelioma | Phase 1 | Terminated | National Cancer Institute (NCI) | 2 | 2021-06-11 | 2024-02-02 |
| Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients Cyclophosphamide, Fludarabine, Aldesleukin - Gastrointestinal Cancer, Pancreatic Cancer | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 5 | 2019-05-16 | 2026-05-19 |
| The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females Zolpidem, ECG - Prostatic Neoplasms | Phase 1 | Terminated | National Cancer Institute (NCI) | 12 | 2019-01-22 | 2026-06-26 |
| Next Generation Personalized Neuroblastoma Therapy Biopsy, Next Generation Sequencing, Tumor Scans - Neuroblastoma, Cancer | Phase 1 | Terminated | Yael P Mosse | 66 | 2016-07-01 | 2026-03-10 |
| Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer EP0057, olaparib, CT scan - Urothelial Carcinoma, Urothelial Cancer | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 45 | 2016-05-09 | 2026-08-13 |
Myelodysplastic Syndromes (2) · Prostatic Neoplasms (2) · Burkitt Lymphoma (1) · Carcinoma (1) · Carcinoma, Transitional Cell (1) · Colonic Neoplasms (1) · Cytopenia (1) · Gastrointestinal Neoplasms (1) · Leukemia, Myeloid, Acute (1) · Lung Neoplasms (1) · Lymphoma, Large B-Cell, Diffuse (1) · Mesothelioma (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Neuroblastoma (1)
National Cancer Institute (NCI) (8) · Yael P Mosse (1)
United States (9)
Najla El Jurdi, M.D. (2) · Anish Thomas, M.D. (1) · James C Yang, M.D. (1) · John M Maris, MD (1) · Mark J Roschewski, M.D. (1) · Raffit Hassan, M.D. (1) · Scott M Norberg, D.O. (1) · William D Figg, Pharm.D. (1)